Compare Stocks

→ Elon to Transform U.S. Economy? (From Porter & Company) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNTTF CannTrust		$9.60	$4.35 ▼ $11.97	$1.01B	4.52	528,025 shs	1.43 million shs
PRNB Principia Biopharma	$100.05	$100.05	$25.35 ▼ $101.89	$3.32B	0.86	729,676 shs	N/A
TXMD TherapeuticsMD	$1.88 -1.1%	$2.18	$1.84 ▼ $4.73	$21.68M	1.07	24,580 shs	24,634 shs
ZIOP ZIOPHARM Oncology		$1.08	$0.77 ▼ $5.95	$187.12M	1.71	2.01 million shs	2.13 million shs

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNTTF CannTrust	0.00%	0.00%	0.00%	0.00%	0.00%
PRNB Principia Biopharma	0.00%	0.00%	0.00%	0.00%	0.00%
TXMD TherapeuticsMD	+0.53%	0.00%	-15.51%	-17.18%	-50.91%
ZIOP ZIOPHARM Oncology	0.00%	0.00%	0.00%	0.00%	0.00%

FW: 234x Gain (Ad)

This coin is an essential building block for an ongoing financial revolution of massive dimensions. As a big part of this revolution, the big banks of the world must connect to the blockchain.

Click here.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CNTTF CannTrust	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PRNB Principia Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TXMD TherapeuticsMD	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ZIOP ZIOPHARM Oncology	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CNTTF CannTrust	N/A	N/A	N/A	N/A
PRNB Principia Biopharma	N/A	N/A	N/A	N/A
TXMD TherapeuticsMD	2.00	Hold	N/A	N/A
ZIOP ZIOPHARM Oncology	N/A	N/A	N/A	N/A

Current Analyst Ratings

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CNTTF CannTrust	$15.96M	0.00	N/A	N/A	N/A	NaN
PRNB Principia Biopharma	$35.16M	94.50	N/A	N/A	$10.95 per share	9.14
TXMD TherapeuticsMD	$1.30M	16.65	N/A	N/A	$2.77 per share	0.68
ZIOP ZIOPHARM Oncology	N/A	N/A	N/A	N/A	$0.58 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CNTTF CannTrust	N/A	$0.07	137.18	0.00	N/A	N/A	N/A	N/A	N/A
PRNB Principia Biopharma	-$53.79M	-$2.09	N/A	N/A	N/A	N/A	-23.08%	-21.11%	N/A
TXMD TherapeuticsMD	-$10.28M	N/A	0.00	∞	N/A	N/A	-25.54%	-14.87%	5/20/2024 (Estimated)
ZIOP ZIOPHARM Oncology	-$79.98M	-$0.43	N/A	N/A	N/A	N/A	-92.84%	-72.46%	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CNTTF CannTrust	N/A	N/A	N/A	N/A	N/A
PRNB Principia Biopharma	N/A	N/A	N/A	N/A	N/A
TXMD TherapeuticsMD	N/A	N/A	N/A	N/A	N/A
ZIOP ZIOPHARM Oncology	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CNTTF CannTrust	N/A	N/A	N/A
PRNB Principia Biopharma	N/A	17.01	17.01
TXMD TherapeuticsMD	N/A	1.72	1.72
ZIOP ZIOPHARM Oncology	0.18	3.43	3.43

Ownership

Institutional Ownership

Company	Institutional Ownership
CNTTF CannTrust	0.08%
PRNB Principia Biopharma	95.54%
TXMD TherapeuticsMD	30.74%
ZIOP ZIOPHARM Oncology	51.03%

Insider Ownership

Company	Insider Ownership
CNTTF CannTrust	N/A
PRNB Principia Biopharma	16.01%
TXMD TherapeuticsMD	1.20%
ZIOP ZIOPHARM Oncology	5.20%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
CNTTF CannTrust	N/A	105.61 million	N/A	Not Optionable
PRNB Principia Biopharma	65	33.21 million	N/A	Not Optionable
TXMD TherapeuticsMD	1	11.53 million	11.39 million	Optionable
ZIOP ZIOPHARM Oncology	105	216.15 million	204.91 million	Optionable

TXMD, CNTTF, PRNB, and ZIOP Headlines

Source	Headline
	Childhood Cancers curetoday.com - February 17 at 5:57 PM
	Alx Oncology Holdings (ALXO) investing.com - February 10 at 8:15 PM
	Pediatric Hematology-Oncology Fellowship bcm.edu - February 5 at 8:39 AM
	Alaunos Therapeutics: Other Events, Financial Statements And Exhibits cbonds.com - January 31 at 9:44 AM
	CG Oncology Inc reuters.com - January 31 at 4:43 AM
	Oncology Nurses' Narratives About Ethical Dilemmas and Prognosis-Related Communication in Advanced Cancer Patients medscape.com - December 21 at 3:43 PM
	Immuno-Oncology ajmc.com - December 19 at 3:21 PM
	Why Is Alaunos Therapeutics (TCRT) Stock Up 37% Today? markets.businessinsider.com - December 18 at 8:18 AM
	Exploring Patient-Centered Handoffs in Surgical Oncology medscape.com - December 10 at 7:36 PM
	Association of Community Cancer Centers ajmc.com - October 14 at 2:50 PM
	Oncology News and Research news-medical.net - September 19 at 5:53 PM
	WBSPH 2024 - Oncology newsweek.com - September 15 at 8:49 PM
	Kris on Oncology medscape.com - September 6 at 11:16 PM
	Gauging Ziopharm's Chances for Positive Sarcoma Drug Trial Results thestreet.com - August 29 at 6:23 AM
	Oncology Cases & Quizzes medscape.com - August 14 at 6:15 PM
	Ziopharm’s palifosfamide fails in first-line STS… investing.com - June 21 at 12:05 AM
	Weber on Oncology medscape.com - June 19 at 2:11 PM
	A Brain, A Heart, and the Courage: Balancing Benefit and Toxicity of Immunotherapy in Melanoma ascopubs.org - June 17 at 8:43 AM
	ALX Oncology Holdings Inc Ordinary Shares morningstar.com - June 15 at 6:54 PM
	Division of Pediatric Hematology and Oncology slu.edu - June 13 at 3:50 PM
	Division of Hematology and Medical Oncology slu.edu - June 13 at 3:50 PM
	Intratumoral Cancer Therapies Global Market Report 2023 finance.yahoo.com - June 9 at 1:32 PM
	Natural Killer Cell Therapy Market 2023-2029 New Research Report by Industryreport.co marketwatch.com - May 11 at 9:52 PM
	VC Identifies 3 Startups That Will Shake Up the Future of Cancer Care medcitynews.com - May 10 at 1:58 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

CannTrust

OTCMKTS:CNTTF

CannTrust Holdings Inc. produces and distributes pharmaceutical grade medical cannabis products in Canada. It sells dried cannabis and oil extractions to the client based on the medication document provided by health care practitioner. The company has a partnership with Gold Coast University Hospital. CannTrust Holdings Inc. was incorporated in 2015 and is headquartered in Vaughan, Canada.

Principia Biopharma

NASDAQ:PRNB

Principia Biopharma Inc., a late-stage biopharmaceutical company, focuses on developing novel therapies for immunology and oncology. The company is developing PRN1008, an inhibitor that is in Phase III clinical trial for the treatment of pemphigus, a chronic skin disease, as well as in Phase II clinical trial to treat immune thrombocytopenic purpura. It is also developing PRN2246/SAR442168, an inhibitor, which has completed Phase I clinical trial for treating multiple sclerosis (MS) and other central nervous system (CNS) diseases; PRN1371, a drug candidate that is in Phase I clinical trial for the treatment of solid tumors; and oral small molecule inhibitors of the immunoproteasome. The company has a collaboration agreement with Genzyme Corporation to develop relapsing and progressive MS and other diseases of the CNS. Principia Biopharma Inc. was incorporated in 2008 and is headquartered in South San Francisco, California.

TherapeuticsMD

NASDAQ:TXMD

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

ZIOPHARM Oncology

NASDAQ:ZIOP

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. Its pipeline includes Sleeping Beauty TCR-T Targeting neoantigens; Ad-RTS-hlL-12 + veledimex; and Sleeping Beauty CAR-T. The company was founded on September 9, 2003 and is headquartered in Boston, MA.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial